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HPLCAbstract A novel comparative force degradation UPLC assay method was developed and validated
for Piracetam and its degradation products. Piracetam was subjected to acid (5 M HCl), neutral
(water) and alkaline (0.5 M NaOH) hydrolytic conditions at 80 C, as well as to oxidative decompo-
sition (H2O2) at room temperature. Photolytic studies were carried out by exposing this drug into
sunlight (60,000–70,000 lux) for 2 d. Additionally, the solid drug was subjected to 50 C for 60 days
in a hot air oven for thermal degradation. The UPLC chromatographic separation was performed on
Acquity UPLC BEH C18 column (1.7 lm, 2.1 mm · 150 mm) using isocratic mode (ACN:water,
25:75 v/v) at a ﬂow rate of 0.15 mL min1 and HPLC chromatographic separation was achieved
on phenomenex C18 using isocratic mode (ACN:10 mM ammonium acetate, pH 5.0, 20:80 v/v) at
a ﬂow rate of 0.9 mL/min. Piracetam was found to degrade only in the base and shows stable behav-
ior under all stress conditions. The UPLC and HPLC linearity of the proposed method was investi-
gated in the range of 10–50 lg mL1. The r2 value of UPLC and HPLC was found to be 0.999 and
0.999, respectively. Method detection limit (MDL) and Method quantiﬁcation limit (MQL) were
found to be 0.180 lg mL1and 1.10 lg mL1 for UPLC and 0.500 lg mL1and 1.700 lg mL1 for
HPLC respectively. The %RSD values for intra-day and inter-day precision were <1.2%, conﬁrm-
ing that the method was sufﬁciently precise. The validation studies were carried out fulﬁlling ICH
requirements. The developed method was simple, fast, accurate and precise and hence could be
applied for routine quality control analysis of Piracetam in solid dosage forms.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The InternationalConference onHarmonization (ICH) for drug
stability test guidelineQ1A (R2) requires that the analysis of sta-
bility samples should be done through the use of validated stabil-
ity-indicating analytical methods. It also recommends carrying
out of stress testing on this drug substance to establish its
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the proposed analytical procedure (ICH, 2003; Junwal et al.,
2012; Dong, 2006; http://pubs.acs.org/subscribe/journals/tcaw/
10/i09/html/09dong.html; Singh et al., 2000; Sahu et al., 2010,
2011).With theobjective of reducing analysis timeandmaintain-
ing constant efﬁciency, there has been a substantial focus on
high-speed chromatographic separations. Recently, a commer-
cially available innovative ultra performance liquid chromatog-
raphy (UPLC) has proven to be one of the most promising
developments in the area of fast chromatographic separations.
The comparative reverse phase chromatographic stability indi-
cating assay method was developed using UPLC and HPLC
for Piracetam bulk drug. Piracetam is a nootropic drug. It shares
the same 2-oxo-pyrrolidone base structure with 2-oxo-pyrroli-
dine carboxylic acid (pyroglutamate). Piracetam is a cyclic deriv-
ative of GABA. It is one of the groups of racetams. Piracetam is
prescribed by doctors for some conditions, mainly myoclonus,
but is used off-label for a much wider range of applications like
aging, alcoholism, alzheimer’s and senile dementia, depression
and anxiety, schizophrenia, closed craniocerebral trauma, pre-
ventive for breath-holding spells etc. The chemical name of
piracetam is 2-oxo-1-pyrrolidineacetamide (Fig. 1) (http://
en.wikipedia.org/wiki/Piracetam; The Merck Index, 2001).
According to the chromatographic performances afforded
by small particles, the latter can be used for two main objec-
tives. First, small particles can be used to perform fast and
ultrafast analyses since a good efﬁciency can be maintained
with short columns and at high ﬂow rates. Second, a high res-
olution can be generated with longer columns, close to the
optimal ﬂow-rate. UPLC has been evaluated in terms of prac-
tical gains in speed and efﬁciency that can be achieved com-
pared with current HPLC systems. Acquity bridge ethylene
hybrid (BEH) 1.7-lm columns are characterized by high opti-
mum velocities (0.37 cm s1) and low minimum plate heights
(4.4 lm) for well-retained compounds (k= 3.6). A slightly
higher-than-expected C-term measured from the experimental
Knox plots is ascribed to a residual temperature effect under
non-ideal adiabatic conditions, lower packing efﬁciency, and
extra-column band broadening. The combination of high opti-
mum ﬂow rates and shorter column lengths enables gains in
speed of factors of approximately 4.3 and 3.5 in comparison
with 5-lm and 3.5-lm particles, respectively, without sacriﬁc-
ing efﬁciency. From the various kinetic plots constructed
according to the method of poppe are evident that the use ofFigure 1 Structure of Piracetam.UPLC instrumentation and columns has advantages in terms
of speed for analyses requiring up to 80,000 theoretical
plates. UPLC seems to be the possibility to extend and elabo-
rate the utility of chromatography. In conclusion, the main
beneﬁts of this relatively new approach of chromatography
are: increased sensitivity, rapid analysis through the use of a
novel separation material of a very ﬁne particle size, decreased
operation cost, less solvent consumption and increased sample
throughput. (Nguyen et al., 2006; Mazzeo et al., 2005; De
Villiers et al., 2006; Wren and Tchelitcheff, 2006).
In the literature, a few methods have been reported for the
estimation of Piracetam by spectrophotometric methods
(Bhowmick et al., 2010), HPLC (El-Saharty, 2008; Augustin
and Imre, 2007), LC-MS/MS (http://pubs.rsc.org; Xianqin
et al., 2010). The major objective of the present work is to de-
velop stress degradation studies of Piracetam under different
ICH recommended stress conditions, and to establish a vali-
dated stability-indicating UPLC/HPLC method for reducing
analysis time and solvents. So far to our knowledge there
was no method that has yet been reported for comparative
UPLC/HPLC method on the development of stability-indicat-
ing assay method for this drug.
2. Experimental
2.1. Chemicals
Piracetam was obtained as a gratis sample from jubilant
organosys (Noida, India). Analytical reagent (AR) Sodium
hydroxide and hydrogen peroxide were purchased from S.D.
Fine-chem. Hydrochloric acid and acetonitrile (99.8%) was
from Merck India (Mumbai). All other chemicals were of ana-
lytical grade.
2.2. Instrumentation
2.2.1. Ultra performance liquid chromatography (UPLC)
UPLC was performed using a Waters Acquity system
equipped with a binary solvent delivery pump, an auto sampler
and a PDA detector. The chromatographic separation was
performed using a Waters Acquity BEH 150 · 2.1 mm,
1.7 lm, C18 column. The mobile phase containing a mixture
of acetonitrile (ACN) and water in the ratio of 25:75 (v/v) at
a ﬂow rate of 0.15 mL min1 was used. The detection was ob-
tained at a wavelength of 210 nm. The injection volume was
2 lL; mobile phase was used as a diluent while the column
was maintained at 30 C. Forced degradation studies were car-
ried out with a photo diode array detector.
2.2.2. High performance liquid chromatography (HPLC)
The HPLC system used for chromatographic development was
shimadzu, separation module with a PDA detector. HPLC sys-
tem (Shimadzu, Japan) consisted of a LC-10AT VP pump, a
SPD-10AVP, PDA detector, a phenomenex C18
(250 mm · 4.6 mm, 5 lm) column, a Phenomenex, HPLC
guard cartridge system and a Class LC10/M10A software. Mo-
bile phase consisting of acetonitrile and buffer (10 mM ammo-
nium acetate, pH 5.0) in the ratio of 20:80 (v/v) in an isocratic
mode with the ﬂow rate of 0.9 mL min1 was employed at
ambient temperature. The injection volume was 20 lL while
the detector was set at 210 nm.
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pH of the mobile phase was checked on a microprocessor
water proof pH tester (pH tester 20, Eutech Instruments, Oak-
ton, USA). The overall illumination at the point of placement
of samples was 6000 lux, which was tested using a calibrated
lux meter (Lutron LX-102 digital light meter, Marcucci
S.P.A, vignate, Milan). Thermal stability study was performed
in a hot air oven (Oven universal with thermotech thermostat
TIC-4000N, S.M. Industries, New Delhi, India).
2.3. Degradation studies
Stress studies were performed under conditions of dry heat
(thermal studies), hydrolysis (acidic, alkaline and neutral), oxi-
dation, and photolysis, as mentioned in ICH Q1A (R2) (1–4).
The approach suggested by Singh and Bakshi was adopted for
these studies. A minimum of four samples were generated for
every stress condition, viz., blank solution stored under normal
conditions, the blank subjected to stress in the same manner as
this drug (Piracetam), a zero time sample containing this drug
(which was stored under normal conditions), and this drug
solution subjected to stress treatment. Hydrolytic decomposi-
tion of Piracetam was conducted at 80 C in 5 M HCl, water,
and 0.5 M NaOH at a drug concentration of 2 mg mL1 until
sufﬁcient degradation (20% of the initial amount) of this
drug was achieved. For oxidative stress studies, Piracetam
was dissolved at a concentration of 3 mg mL1 in 30% H2O2
and kept for two days at room temperature. Photolytic studies
of the dry drug and this drug in solution in acetonitrile at a
concentration of 2 mg mL1 were performed by exposure to
sunlight during the daytime (60,000–70,000 lux) for 2 d.
2.4. Chromatography and development of a stability-indicating
method
UPLC was performed with a binary solvent delivery pump, an
auto sampler and a PDA detector of Acquity UPLC system
manufactured by Waters Corporation; Milford, Massachu-
setts, USA; data were acquired and processed using Empower
software. An initial literature search revealed that some re-
ported HPLC methods for Piracetam were developed on either
C8 or C18 columns, using different temperature conditions.
Peak shapes were not persuasive, and there was substantial
tailing. So, attempts were made to develop a simple method
on an advanced BEH C18 column, with possible lowering of
retention time at 30 C column temperature. Separations were
achieved using isocratic elution. The mobile phase was ﬁltered
through 0.22 lm PTFE membranes and had degassed. The
injection volume was 2 lL and the mobile phase ﬂow rate
was kept constant at 0.15 mL min1. The detection wavelength
was 210 nm; PDA analysis was conducted to study the behav-
ior at other wavelengths. First, UPLC studies were performed
on all reaction solutions individually and then on a mixture of
degraded drug solutions. Different conditions, for example
pH, mobile phase composition, and column temperature were
varied to obtain a reasonable separation between this drug and
the degradation products. Methanol was avoided during the
study because of its signiﬁcant absorption at the detection
wavelength of this drug between 210 and 215 nm. Acquity
UPLC BEH C18 column (1.7 lm, 2.1 mm · 150 mm) stainless
steel analytical column was used as stationary phase. In orderto determine the method is stability indicating, forced degrada-
tion studies were conducted on Piracetam powder. The analy-
sis was carried out by UPLC with a PDA detector at a
wavelength of 210. Two microliters of each of forced degrada-
tion samples was injected at regular intervals.
HPLC chromatographic analysis was performed at ambient
temperature on a Phenomenex (C-18) analytical column with a
mobile phase composed of buffer (10 mM Amm. Acetate buf-
fer pH 5.0): acetonitrile (80:20, v/v) and was isocratically
eluted at a ﬂow rate of 0.9 mL min1. A small sample volume
of 20 lL was used for each sample run, being injected into the
HPLC system. The chromatogram was monitored with UV
detection at a wavelength of 210 nm.
2.5. Validation of the method
The method was validated in accordance with ICH guidelines
Q2 (R1). To establish linearity and range, a stock solution con-
taining 1 mg mL1 drug in acetonitrile was diluted to yield
solutions in the concentration range of 10–50 lg mL1. The
solutions were injected in triplicate using water–acetonitrile
as mobile phase and keeping the injection volume constant
(2 lL). To assess precision, six injections of ﬁve different con-
centrations (10, 20, 30, 40, and 50 lg mL1) were made on the
same day and intraday precision was determined as relative
standard deviation. These studies were also repeated on differ-
ent days to determine interday precision. Accuracy was evalu-
ated by fortifying a mixture of decomposed reaction solutions
with ﬁve known concentrations of this drug and recovery of
the added drug was evaluated. The speciﬁcity of the method
for this drug was established by a study of the resolution factor
of this drug peak from the nearest other peak. Overall selectiv-
ity was established by the determination of purity for each deg-
radation product peak by the use of PDA detector. Robustness
was assessed by changing the composition of mobile phase.
Method detection limit (MDL) and method quantiﬁcation lim-
it (MQL) were determined experimentally, by an analysis of
samples spiked with decreasing concentrations of the analytes.
MDL was deﬁned as the smallest amount of an analyte that
can be reliably detected or differentiated from the background
for a particular matrix (by a speciﬁc method). MQL was calcu-
lated as the smallest amount of an analyte that can be reliably
quantiﬁed with a certain degree of reliability within a particu-
lar matrix (by a speciﬁc method). In chromatography methods,
the limits are often set based on the ratio between the analyte
signal and the baseline noise (for example, MDL= Height/
Noise ratio of 3, MQL= Height/Noise ratio of 10).
3. Results and discussion
3.1. UPLC and HPLC studies on the stressed solutions
The forced-degradation study shows that Piracetam degraded
under alkali stress condition. The speciﬁcity and selectivity of
the method with the samples under these stresses were demon-
strated through the evaluation of RT, RRT, resolution, and
purity data for all peaks in the chromatograms (http://
www.chem.agilent.com/Library/posters/Public/ASMS_2011_
MP_181.pdf; Singh and Bakshi, 2002; Singh et al., 2006).
Piracetam did not degrade under acid, oxidative, thermal &
photolytic stress conditions. In a mixture of solution, only
Table 1 Retention times and relative retention times of various peaks.
Peaks UPLC HPLC
Retention time (RT) Relative retention time (RRT) Retention time (RT) Relative retention time (RRT)
Deg01 2.05 0.576 2.75 0.370
Piracetam 3.56 1.000 7.44 1.000
RT, retention time (min); RRT, relative retention time.
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and relative retention times (RRT) of this drug and the degra-
dation products are given in Table 1 for UPLC and HPLC.
This drug and degradation products carry the notations
Deg01 and Piracetam in accordance with the sequence in
which the peaks appeared from left to right on UPLC and
HPLC chromatogram (mixture of stressed sample) (Fig. 2).
Ultra-performance liquid chromatography (UPLC) is a new
category of separation technique based upon well-established
principles of liquid chromatography, which utilizes sub-1.7 l
particles for a stationary phase. These particles operate at ele-
vated mobile phase linear velocities to affect a dramatic in-
crease in resolution, sensitivity and speed of analysis.
3.2. Development and optimization of the method
3.2.1. UPLC
The best separation was achieved on the same column at 30 C
using the mobile phase acetonitrile: water (70:30) in anFigure 2 Chromatogram showing separation of Piracetam and its de
and (b) HPLC.isocratic mode. The ﬂow rate was kept at 0.15 mL min1 at
a constant volume of 2 lL, and the detection wavelength was
210 nm. UPLC studies on Piracetam under different stress
conditions suggested the following degradation behaviors:
Piracetam gradually degraded with time on heating at 80 C
in 0.5 M NaOH after 10 h. The drug showed 25% degrada-
tion in 0.5 M NaOH at 80 C. A new peak emerged at Rt
2.05 min along with the drug peak at Rt 3.56 (RRT 1.00). In
a mixture of the stressed samples (Fig. 2(a)), the degradation
product at RRT 0.576 (with the normal drug peak at RRT
1.0) pertained to Deg01. The drug was stable to acidic stress,
and it was observed that the drug was not degraded by heating
at 80 C in 5 M HCl for 24 h. the drug shows stable behavior
at neutral hydrolysis on heating with water at 80 C for two
days. No degradation was observed on exposure of the drug
to 30% H2O2 for ﬁve days, showing that it was stable against
oxidative stress. The drug was also stable during exposure to
direct sunlight (60,000–70,000 lux) for two days. Finally,
there was no signiﬁcant degradation of solid piracetam ongradation products in a mixture of stressed samples by (a) UPLC
Table 2 Data for Piracetam from linearity studies (n= 6).
UPLC HPLC
Concentration (lg mL1) AUC ±SD RSD (%) Concentration (lg mL1) AUC ±SD RSD (%)
10 53163.00 50.402 0.095 10 1875032.7 17315.0 0.923
20 107907.00 80.829 0.075 20 3570996.0 11523.4 0.323
30 153736.64 625.167 0.407 30 5458691.7 5756.8 0.105
40 208638.00 555.698 0.266 40 7159961.3 34627.7 0.484
50 259296.99 601.775 0.232 50 9059744.7 34816.7 0.384
SD, standard deviation; RSD, relative standard deviation; AUC, area under curve.
Table 3 Data of intra-day and inter-day precision studies (n= 4).
Actual concentration (lg mL1) Intra-day Inter-day
Measured concentration ±SD RSD (%) Measured concentration ±SD RSD (%)
UPLC
10 9.958 0.030 0.304 9.9627 0.0866 0.8691
20 20.173 0.084 0.417 20.1067 0.1557 0.7742
30 30.059 0.210 0.700 29.7853 0.1622 0.5445
40 40.246 0.467 1.160 39.9067 0.2068 0.5183
50 50.044 0.314 0.628 49.8867 0.1881 0.3771
HPLC
10 9.934 0.051 0.514 9.9670 0.0260 0.2609
20 20.123 0.150 0.746 20.1995 0.0705 0.3490
30 30.022 0.187 0.622 30.0030 0.1870 0.6233
40 40.129 0.407 1.015 40.1035 0.3965 0.9887
50 49.977 0.257 0.514 49.9455 0.2645 0.5296
SD, standard deviation; RSD, relative standard deviation.
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the drug was stable to thermal stress.
3.2.2. HPLC
As UPLC, the same degradation product appeared in HPLC
as shown in Fig. 2(b). In alkali, the drug was found to decom-
pose gradually, similar to the behavior observed in UPLC. The
drug was degraded (25% degradation) in 0.5 M NaOH at
80 C at 10 h, and one peak was generated, at Rt 2.75. In a
mixture of stressed samples the degradation product appeared
at RRT 0.576, the retention time of Deg01. On heating at 80 C
in 5 M HCl for 24 h, the height of the drug peak was not de-
creased, which shows that the drug was stable in acidic stress
conditions. Similarly, the drug shows stable behavior against
the oxidative, thermal and photolytic stress conditions.
3.3. Validation of developed stability-indicating method
The response for this drug was strictly linear in the concentra-
tion range between 10 and 50 lg mL1. The linearity study
data are given in Table 2.
Regression equation
Y ¼ 5129Xþ 2648 ðUPLC r2 ¼ 0:999; intercept ¼ 2648Þ
Y ¼ 17958Xþ 37368 ðHPLC r2 ¼ 0:999; intercept ¼ 37368Þ
Y ¼ AUC; X ¼ conc: in lg mL1The data obtained from precision experiments are given in
Table 3 for intra and inter day precision studies. The %RSD.
values for intraday precision study and for interday study were
<1.0% conﬁrming that the method was sufﬁciently precise.
Excellent recoveries were made at each added concentration
shown in Table 4. Fig. 2(a) and (b) shows that the method
was sufﬁciently speciﬁc to this drug. The USP resolution factor
for this drug peak was >2 from the nearest resolving peak.
The method was found to be robust by varying the composi-
tion of mobile phase as shown in Table 5. Good separations
were always achieved, indicating that the method remained
selective for all components under the tested conditions as
shown in Fig. 2(a) and (b). The inﬂuence of retention time
for different degradation products (UPLC/HPLC) has been
depicted in Fig. 2.
The MDL and MQL were found to be 0.180 lg mL1and
1.10 lg mL1 for UPLC and 0.500 lg mL1 and
1.700 lg mL1respectively for HPLC.3.4. Comparative study on chromatographic performance
A comparative data on the chromatographic performance of
HPLC (isocratic) and UPLC (isocratic) have been obtained
by injecting a mixture of stressed solution of Piracetam
(30 lg mL1). It is observed that the elution time of pure
Piracetam and degradation products in UPLC was reduced
Table 4 Recovery data for Piracetam spiked into a mixture of stressed samples (n= 4).
Concentration (lg mL1) Calculated spiked concentration ±S.D. RSD. (%) Recovery (%)
UPLC
10 9.889 0.055 0.557 98.893
20 20.527 0.457 2.226 102.635
30 29.792 0.101 0.340 99.307
40 39.740 0.556 1.399 99.351
50 49.714 0.619 1.244 99.428
HPLC
10 9.978 0.061 0.616 99.777
20 20.130 0.125 0.620 100.650
30 29.942 0.132 0.442 99.807
40 39.976 0.233 0.583 99.939
50 49.934 0.219 0.439 99.867
SD, standard deviation; RSD, relative standard deviation.
Table 5 Data for robustness.
Concentration (lg mL1) Acetonitrile: H2O (22:78 v/v) Acetonitrile: H2O (27:73 v/v)
Measured concentration ±SD RSD (%) Measured concentration ±SD RSD (%)
UPLC (n = 3)
10 9.944 0.047 0.469 9.948 0.042 0.422
20 20.173 0.084 0.416 20.123 0.150 0.746
30 30.055 0.207 0.690 30.025 0.191 0.636
40 40.252 0.472 1.173 40.122 0.398 0.992
50 50.010 0.293 0.585 50.010 0.287 0.575
HPLC(n = 3)
Acetonitrile: 10 mM Amm. acetate (17:83 v/v) Acetonitrile: 10 mM Amm. acetate (22:78 v/v)
10 9.938 0.048 0.482 9.941 0.045 0.456
20 20.090 0.159 0.790 20.163 0.122 0.606
30 29.989 0.150 0.499 30.022 0.184 0.613
40 39.989 0.246 0.615 40.122 0.427 1.064
50 49.964 0.247 0.495 49.964 0.247 0.495
UPLC, ultra performace liquid chromatography; HPLC, high performance liquid chromatography; n, number of replicates.
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olution and theoretical plates obtained for Piracetam and deg-
radation products in UPLC showed comparatively a better
separation efﬁciency than HPLC.
4. Conclusions
The validated stability-indicating method was established for
the analysis of Piracetam in the presence of its degradation
products as per ICH recommendations. In the present work,
UPLC and HPLC methods were used to assess degradation
products’ peaks during a stress testing analysis of Piracetam
drug substance. The newly developed UPLC method for the
separation of different degradation products along with the
pure drug of Piracetam was found to be capable of giving fas-
ter retention times while still maintaining satisfactory resolu-
tion than that achieved with conventional HPLC. The drug
is only degrading in alkaline conditions conﬁrmed by theemerging of single degradation product in a mixture of stress
samples. The speciﬁcity and selectivity of the method with
the samples under these stresses were demonstrated through
the evaluation of RT, RRT, resolution, and purity data for
all peaks in the chromatograms using PDA detector. Pirace-
tam did not degrade on acidic, neutral, thermal & photolytic
stresses. The method was fully validated showing satisfactory
data for all the parameters tested. This method exhibited an
excellent performance in terms of sensitivity and speed. The
method proved to be simple, accurate, precise, speciﬁc and
selective. It is hoped that the developed method is stability
indicating which can be used for the impurity testing and assay
determination in the routine analysis of production samples as
well as to analyze stability samples.
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